<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.450">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Jess Scrimshire">
<meta name="dcterms.date" content="2024-03-24">

<title>Topic modelling cannot identify immediate changes to research themes in Alzheimer’s Disease around the accelerated approval of lecanemab</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="report_files/libs/clipboard/clipboard.min.js"></script>
<script src="report_files/libs/quarto-html/quarto.js"></script>
<script src="report_files/libs/quarto-html/popper.min.js"></script>
<script src="report_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="report_files/libs/quarto-html/anchor.min.js"></script>
<link href="report_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="report_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="report_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="report_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="report_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">

  <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

</head>

<body>

<div id="quarto-content" class="page-columns page-rows-contents page-layout-full toc-left">
<div id="quarto-sidebar-toc-left" class="sidebar toc-left">
  <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#abstract" id="toc-abstract" class="nav-link active" data-scroll-target="#abstract">Abstract</a></li>
  <li><a href="#introduction" id="toc-introduction" class="nav-link" data-scroll-target="#introduction">Introduction</a>
  <ul class="collapse">
  <li><a href="#alzheimers-disease" id="toc-alzheimers-disease" class="nav-link" data-scroll-target="#alzheimers-disease">Alzheimer’s Disease</a></li>
  <li><a href="#treatments-for-ad" id="toc-treatments-for-ad" class="nav-link" data-scroll-target="#treatments-for-ad">Treatments for AD</a></li>
  <li><a href="#text-mining-and-topic-modelling-in-ad-research" id="toc-text-mining-and-topic-modelling-in-ad-research" class="nav-link" data-scroll-target="#text-mining-and-topic-modelling-in-ad-research">Text Mining and Topic Modelling in AD Research</a></li>
  <li><a href="#aims-and-hypotheses" id="toc-aims-and-hypotheses" class="nav-link" data-scroll-target="#aims-and-hypotheses">Aims and Hypotheses</a></li>
  </ul></li>
  <li><a href="#methods" id="toc-methods" class="nav-link" data-scroll-target="#methods">Methods</a>
  <ul class="collapse">
  <li><a href="#data-acquisition" id="toc-data-acquisition" class="nav-link" data-scroll-target="#data-acquisition">Data Acquisition</a>
  <ul class="collapse">
  <li><a href="#litsearchr" id="toc-litsearchr" class="nav-link" data-scroll-target="#litsearchr"><em>litsearchR</em></a></li>
  </ul></li>
  <li><a href="#data-preprocessing" id="toc-data-preprocessing" class="nav-link" data-scroll-target="#data-preprocessing">Data Preprocessing</a></li>
  <li><a href="#data-analysis" id="toc-data-analysis" class="nav-link" data-scroll-target="#data-analysis">Data Analysis</a>
  <ul class="collapse">
  <li><a href="#metadata-analysis" id="toc-metadata-analysis" class="nav-link" data-scroll-target="#metadata-analysis">Metadata Analysis</a></li>
  <li><a href="#term-frequency" id="toc-term-frequency" class="nav-link" data-scroll-target="#term-frequency">Term Frequency</a></li>
  <li><a href="#topic-modelling" id="toc-topic-modelling" class="nav-link" data-scroll-target="#topic-modelling">Topic Modelling</a></li>
  </ul></li>
  </ul></li>
  <li><a href="#results-and-discussion" id="toc-results-and-discussion" class="nav-link" data-scroll-target="#results-and-discussion">Results and Discussion</a>
  <ul class="collapse">
  <li><a href="#search-query-refinement-identified-the-term-alzheimer" id="toc-search-query-refinement-identified-the-term-alzheimer" class="nav-link" data-scroll-target="#search-query-refinement-identified-the-term-alzheimer">Search Query Refinement Identified the Term ‘alzheimer’</a></li>
  <li><a href="#ad-research-publication-frequency-is-not-associated-with-lecanemab-approval" id="toc-ad-research-publication-frequency-is-not-associated-with-lecanemab-approval" class="nav-link" data-scroll-target="#ad-research-publication-frequency-is-not-associated-with-lecanemab-approval">AD Research Publication Frequency is not Associated with Lecanemab Approval</a>
  <ul class="collapse">
  <li><a href="#research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval" id="toc-research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval" class="nav-link" data-scroll-target="#research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval">Research concerning genetic risk and molecular pathology were prominent before lecanemab underwent accelerated approval</a></li>
  <li><a href="#research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval-1" id="toc-research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval-1" class="nav-link" data-scroll-target="#research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval-1">Research concerning genetic risk and molecular pathology were prominent before lecanemab underwent accelerated approval</a></li>
  <li><a href="#tau-research-may-be-increasing-after-lecanemab-accelerated-approval." id="toc-tau-research-may-be-increasing-after-lecanemab-accelerated-approval." class="nav-link" data-scroll-target="#tau-research-may-be-increasing-after-lecanemab-accelerated-approval.">Tau research may be increasing after lecanemab accelerated approval.</a></li>
  </ul></li>
  </ul></li>
  
  </ul>
</nav>
</div>
<div id="quarto-margin-sidebar" class="sidebar margin-sidebar zindex-bottom">
</div>
<main class="content column-page-right" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Topic modelling cannot identify immediate changes to research themes in Alzheimer’s Disease around the accelerated approval of lecanemab</h1>
</div>



<div class="quarto-title-meta">

    <div>
    <div class="quarto-title-meta-heading">Author</div>
    <div class="quarto-title-meta-contents">
             <p>Jess Scrimshire </p>
          </div>
  </div>
    
    <div>
    <div class="quarto-title-meta-heading">Published</div>
    <div class="quarto-title-meta-contents">
      <p class="date">March 24, 2024</p>
    </div>
  </div>
  
    
  </div>
  

</header>

<table class="table">
<thead>
<tr class="header">
<th></th>
<th>Estimated Words (~2800)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Introduction</td>
<td>873</td>
</tr>
<tr class="even">
<td>Methods</td>
<td>775</td>
</tr>
<tr class="odd">
<td>Results &amp; Discussion</td>
<td>1191</td>
</tr>
<tr class="even">
<td>Abstract</td>
<td>157</td>
</tr>
</tbody>
</table>
<section id="abstract" class="level1">
<h1>Abstract</h1>
<p>Every year thousands of scientific articles are published concerning the chronic neurodegenerative disorder and leading cause of dementia, Alzheimer’s disease (AD). Currently there are no treatments that cure AD, however recently the anti-amyloid immunotherapy lecanemab has been granted accelerated approval by the FDA. Using text mining and topic modelling, full abstract text between 01-01-2022 and 30-12-2023, and containing the MeSH term “Alzheimer’s Disease” from PubMed and preprint databases, were allocated to two corpuses determined by the accelerated approval date for lecanemab, 06-01-2023. Despite the frequency of literature increasing concerning terms relating to lecanumab, references to cellular and molecular pathology has remained consistent surrounding its approval. Increasing probabilities for the unigrams, ‘tau’ and ‘placebo’ may suggest the research is shifting towards new therapeutic targets and advances in later phase clinical trials, however a longer follow up period will be necessary to draw these conclusions.</p>
</section>
<section id="introduction" class="level1">
<h1>Introduction</h1>
<section id="alzheimers-disease" class="level2">
<h2 class="anchored" data-anchor-id="alzheimers-disease">Alzheimer’s Disease</h2>
<p>Alzheimer’s disease (AD) is a chronic neurodegenerative disease affecting over 55 million people worldwide, and is the most common cause of dementia <span class="citation" data-cites="World_Health_Organization2023-eb">(<a href="#ref-World_Health_Organization2023-eb" role="doc-biblioref">1</a>)</span>. The predominant symptoms of AD usually manifest after the age of 65 and include cognitive impairment, physical and emotional difficulties <span class="citation" data-cites="2023_Alzheimers_disease_facts_and_figures2023-ek">(<a href="#ref-2023_Alzheimers_disease_facts_and_figures2023-ek" role="doc-biblioref">2</a>)</span>. The mechanisms determining the progression of AD are not fully understood, but many agree on the amyloid or tau hypotheses, originating from the presence of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles frequently found in the brains of patients with AD <span class="citation" data-cites="Villemagne2013-xk Iaccarino2018-ta">(<a href="#ref-Villemagne2013-xk" role="doc-biblioref">3</a>,<a href="#ref-Iaccarino2018-ta" role="doc-biblioref">4</a>)</span>. These abnormal proteins lead to disruptions in neuronal signalling pathways and may result in cortical and hippocampal atrophy leading to cognitive decline in AD patients.</p>
<p>AD diagnosis requires the presence of both amyloid and tau pathologies, and signs of neuroinflammation, neuronal death and brain atrophy <span class="citation" data-cites="Garcia-Morales2021-zb">(<a href="#ref-Garcia-Morales2021-zb" role="doc-biblioref">5</a>)</span>. Biomarkers of neuroinflammation can be found in cerebrospinal fluid (CSF) and blood plasma <span class="citation" data-cites="Janeiro2021-sg">(<a href="#ref-Janeiro2021-sg" role="doc-biblioref">6</a>)</span> and brain atrophy can be measured with techniques such as magnetic resonance imaging <span class="citation" data-cites="Odusami2021-pp">(<a href="#ref-Odusami2021-pp" role="doc-biblioref">7</a>)</span>. Physiological changes in the brain develop before the onset of symptoms which makes it difficult to find treatments when many patients are diagnosed with AD after irreversible neuronal death and hippocampal damage.</p>
<p>AD has multiple risk factors suggesting age, epigentic modifiers, infectious agents, and diet all contribute to the development of AD <span class="citation" data-cites="A_Armstrong2019-go Henderson1988-cr">(<a href="#ref-A_Armstrong2019-go" role="doc-biblioref">8</a>,<a href="#ref-Henderson1988-cr" role="doc-biblioref">9</a>)</span>. An epidemiological comparison of people aged 65 years and older from two different decades, suggested that the prevalence of AD is decreasing due to the increase in healthcare resources <span class="citation" data-cites="Matthews2013-vu">(<a href="#ref-Matthews2013-vu" role="doc-biblioref">10</a>)</span>.</p>
</section>
<section id="treatments-for-ad" class="level2">
<h2 class="anchored" data-anchor-id="treatments-for-ad">Treatments for AD</h2>
<p>There are currently no therapies or interventions that can cure AD, but several approved treatments exist to manage cognitive impairment, to alleviate symptoms, and enhance the overall quality of life for patients. Acetylcholinesterase inhibitors (AchE) aim to increase the levels of the neurotransmitter acetylcholine which are attenuated during the pathologies of AD and associated with the loss of cholinergic neurons <span class="citation" data-cites="Colovic2013-it">(<a href="#ref-Colovic2013-it" role="doc-biblioref">11</a>)</span>. Whilst AchEs provide many benefits to treat the symptoms of AD, they do not delay or stop the progression of the disease and the effects may only last for 12-24 months <span class="citation" data-cites="Courtney2004-br">(<a href="#ref-Courtney2004-br" role="doc-biblioref">12</a>)</span>. Mementine is a NMDA receptor antagonist to inhibit glutamate mediated neurotoxicity as neurons die during AD progression <span class="citation" data-cites="Long2019-qm">(<a href="#ref-Long2019-qm" role="doc-biblioref">13</a>)</span>. Memantine has been approved for moderate severe to severe AD, however the drug has not been shown to slow the progression of the disease or prove effective in mild-to-moderate stages of the disease <span class="citation" data-cites="Folch2018-vb Rogawski2003-od">(<a href="#ref-Folch2018-vb" role="doc-biblioref">14</a>,<a href="#ref-Rogawski2003-od" role="doc-biblioref">15</a>)</span>.</p>
<p>Two anti-amyloid human monoclonal immunotherapies, aducanumab and lecanemab, have recently been granted approval by the United States Food and Drug Administration (US FDA) <span class="citation" data-cites="Center_for_Drug_Evaluation2023-gy Office_of_the_Commissioner2023-hu">(<a href="#ref-Center_for_Drug_Evaluation2023-gy" role="doc-biblioref">16</a>,<a href="#ref-Office_of_the_Commissioner2023-hu" role="doc-biblioref">17</a>)</span>. Aducanumab approval was rejected by the European Medicines Agency (EMA) due to the conflicting phase III clinical trial evidence and concerns over patient safety <span class="citation" data-cites="Alexander2021-ln Mahase2021-no">(<a href="#ref-Alexander2021-ln" role="doc-biblioref">18</a>,<a href="#ref-Mahase2021-no" role="doc-biblioref">19</a>)</span>, whereas lecanumab is currently under review by the EMA for approval <span class="citation" data-cites="noauthor_undated-ml">(<a href="#ref-noauthor_undated-ml" role="doc-biblioref">20</a>)</span>. Aducanemab targets the soluble Aβ oligomers and insoluble fibrils whereas lecanumab targets the soluble Aβ protofibrils, but both led to the development of severe adverse events including amyloid-related imaging abnormalities (ARIA) <span class="citation" data-cites="Sevigny2016-yx Brenman2023-ki">(<a href="#ref-Sevigny2016-yx" role="doc-biblioref">21</a>,<a href="#ref-Brenman2023-ki" role="doc-biblioref">22</a>)</span>. These results suggest further research is needed to understand the full molecular causes of AD to help find safe yet effective treatments.</p>
<p>Recent comprehensive reviews have identified a shift in research with more Phase I studies being conducted and four more anti-amyloid monoclonal antibody treatments having completing or currently undergoing Phase III clinical trials <span class="citation" data-cites="Cummings2023-lo Huang2023-vq">(<a href="#ref-Cummings2023-lo" role="doc-biblioref">23</a>,<a href="#ref-Huang2023-vq" role="doc-biblioref">24</a>)</span>. These trials are involving more patients with early onset AD and mild cognitive impairment (MCI) to help develop preventative therapies. Global estimates for people living with preclinical AD or positive for AD pathology biomarkers were 69 and 315 million, respectively <span class="citation" data-cites="Gustavsson2023-qr">(<a href="#ref-Gustavsson2023-qr" role="doc-biblioref">25</a>)</span>, therefore increasing research focus on these patient populations is imperative to slow the progression of the disease. Clinical trials including disease modifying therapies targeting tau have also increased with most in phase I studies, therefore research may be shifting to the other pathological hypotheses of AD to identify treatments. These reviews have not been updated since the accelerated approval of lecanemab, therefore we aim to identify whether there is a transition in research topics.</p>
</section>
<section id="text-mining-and-topic-modelling-in-ad-research" class="level2">
<h2 class="anchored" data-anchor-id="text-mining-and-topic-modelling-in-ad-research">Text Mining and Topic Modelling in AD Research</h2>
<p>Thousands of articles are published every year concerning AD, so focusing on early-stage drug discovery could lead to more literature and clinical findings being identified. Systematic reviews and meta-analyses however, are time consuming and labour intensive, and pose a significant challenge to updating the current understandings in the research literature <span class="citation" data-cites="Higgins2019-kn">(<a href="#ref-Higgins2019-kn" role="doc-biblioref">26</a>)</span>. Topic modelling, a prominent text mining technique, can find patterns and relationships within natural language data, and could provide an automated and unbiased overview of research text. The most common topic modelling method is Latent Dirichlet Allocation (LDA) which assumes, for unstructured text data like research publication, that each document is made up of a number of topics and that each topic is made up of a collection of words <span class="citation" data-cites="Blei2003-lh">(<a href="#ref-Blei2003-lh" role="doc-biblioref">27</a>)</span>. Each LDA topic is represented as a probability of words within a topic and a probability of topics within each document, which each follow a Dirichlet distribution.</p>
<p><em>In silico</em> topic modelling has been used for various applications relating to AD, including describing the research landscape <span class="citation" data-cites="Martinelli2022-ic">(<a href="#ref-Martinelli2022-ic" role="doc-biblioref">28</a>)</span>, identifying novel biomarkers <span class="citation" data-cites="Greco2012-pv">(<a href="#ref-Greco2012-pv" role="doc-biblioref">29</a>)</span>, and drug repurposing <span class="citation" data-cites="Nian2022-xw">(<a href="#ref-Nian2022-xw" role="doc-biblioref">30</a>)</span>. Martinelli <span class="citation" data-cites="Martinelli2022-ic">(<a href="#ref-Martinelli2022-ic" role="doc-biblioref">28</a>)</span> performed a nine-topic LDA model and identified five mechanistic themes, one topic relating to AD diagnosis and three concerning treatments. <em>Any publication relating to using LDA to update knowledge with a shift in the literature.</em> To the best of my knowledge, no studies have explored the change to the AD research landscape with the emergence of newly approved immunotherapy treatments.</p>
</section>
<section id="aims-and-hypotheses" class="level2">
<h2 class="anchored" data-anchor-id="aims-and-hypotheses">Aims and Hypotheses</h2>
<p>Vast quantities of literature are being published annually concerning AD. We aim to comprehensively characterise AD research through the period that the AD immunotherapy drug, lecanemab, underwent accelerated approval for early AD on the 6th July 2023. We hypothesise that new treatments targeting the pathophysiological changes in patients with AD, represent a major paradigm shift in AD research. We propose that LDA topic models can help identify distinct thematic changes in the literature. We will identify whether theses methods can summarise the latest research are crucial for making significant strides in understanding the complexities of this disease and finding new ways to treat AD. Furthermore, this method could be translated to other neurodegenerative disease and to study the impact of emerging novel treatment options.</p>
</section>
</section>
<section id="methods" class="level1">
<h1>Methods</h1>
<p>A full summary of the methodology is provided in <a href="#fig-full-summary">Figure&nbsp;1</a>. All data analysis and visualisations were done in R version 4.3.2 using <em>tidyverse</em> packages <span class="citation" data-cites="Wickham2019-rj">(<a href="#ref-Wickham2019-rj" role="doc-biblioref">31</a>)</span> unless otherwise stated.</p>
<div id="fig-full-summary" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-hash="report_cache/html/fig-full-summary_8e4876835ddf74f8e6d32bb01d2e4ecd">
<div class="cell-output-display">
<div id="fig-full-summary" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="data/methodsummary.png" class="img-fluid figure-img" data-ref-parent="fig-full-summary" width="480"></p>
<figcaption class="figure-caption">(a)</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;1: <strong>Summary of Methods.</strong> Abstracts gathered from PubMed then updated with <em>litsearchr</em> results, or from preprint databases were read into R. Meta data analysis was performed then text was tidied and tokenised, then allocated to two corpuses relative to the accelerated approval date of lecanemab. LDA topic modelling and n-gram analysis results were collected then interpreted.</figcaption>
</figure>
</div>
<section id="data-acquisition" class="level2">
<h2 class="anchored" data-anchor-id="data-acquisition">Data Acquisition</h2>
<p>Due to accessing constraints, abstracts represent the only document content for this study. Titles, full abstract text, and publication date were obtained from the National Center for Biotechnology Information (NCBI) datasbase, PubMed, using the inclusion criteria described in <a href="#tbl-inclusion-criteria">Table&nbsp;1</a>, and accessed through <em>Rismed</em> <span class="citation" data-cites="Kovalchik2021-xq">(<a href="#ref-Kovalchik2021-xq" role="doc-biblioref">32</a>)</span> on 18-02-2024. Results from PubMed were combined with publications from the preprint data sources, bioRxiv and medXriv, using <em>medrxiv</em> <span class="citation" data-cites="medrxivr">(<a href="#ref-medrxivr" role="doc-biblioref"><strong>medrxivr?</strong></a>)</span>. An additional dataset was generated for abstracts containing the associated terminology for the AD drug lecanemab: ‘<em>lecanemab</em>’, ‘<em>leqembi</em>’ ‘<em>BAN2401</em>’, and ‘<em>mAb158</em>’. The diversity of entries into the PubMed database ensures that the contents are representative and studies are reliable as they are obtained from multiple sources. Entries are assigned Medical Subject Headings (MeSH) which identify health-related terms within each document, therefore classifying articles according to their subject nature which reduces potential interpretive bias.</p>
<div id="tbl-inclusion-criteria" class="anchored">
<table class="table">
<caption>Table&nbsp;1: <strong>Inclusion criteria used to query and identify all relevant terms concerning AD in the PubMed database.</strong> Adapted from <span class="citation" data-cites="Martinelli2022-ic">(<a href="#ref-Martinelli2022-ic" role="doc-biblioref">28</a>)</span>.</caption>
<colgroup>
<col style="width: 37%">
<col style="width: 62%">
</colgroup>
<thead>
<tr class="header">
<th>Criteria</th>
<th>Filter Applied</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>MeSH Term</td>
<td>‘Alzheimer’s Disease’</td>
</tr>
<tr class="even">
<td>Title and/or Abstract Text</td>
<td><p>‘Alzheimer’s Disease’</p>
<p>‘AD’</p></td>
</tr>
<tr class="odd">
<td>Article Type</td>
<td><p>“Books”</p>
<p>“Case Reports”</p>
<p>“Clinical Study”</p>
<p>“Clinical Trial”</p>
<p>“Controlled Clinical Trial”</p>
<p>“Meta-analysis”</p>
<p>“Randomised Controlled Trial”</p>
<p>“Review”</p>
<p>“Systematic Review”</p></td>
</tr>
<tr class="even">
<td>Publication Date</td>
<td>1st January 2022 to 1st January 2024 inclusive</td>
</tr>
<tr class="odd">
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>
</div>
<section id="litsearchr" class="level3">
<h3 class="anchored" data-anchor-id="litsearchr"><em>litsearchR</em></h3>
<p>To reassure us that the PubMed search query encapsulated all literature, <em>litsearchr</em> package was used to expand the search terms <span class="citation" data-cites="Grames2019-as">(<a href="#ref-Grames2019-as" role="doc-biblioref">33</a>)</span>. Citations from PubMed results using the previous search criteria in <a href="#tbl-inclusion-criteria">Table&nbsp;1</a> were read into R. The combined unique keyword and titles, as not all articles have keywords, for each result were collected. To ensure only the most relevant terms were searched, stop words were removed, as previously described, and the minimum frequency of words for keywords and title was set to n = 50 and n = 75, respectively. A matrix of each word in each article was created and the potential search terms were ranked with <em>create_network</em> and <em>strength</em> <span class="citation" data-cites="Barrat2004-hm">(<a href="#ref-Barrat2004-hm" role="doc-biblioref">34</a>)</span> from the <em>igraph</em> package <span class="citation" data-cites="Csardi2006-gb">(<a href="#ref-Csardi2006-gb" role="doc-biblioref">35</a>)</span>. The change point method calculated the optimal cutoff positions based on the trend in sharp changes for <em>strength</em>.</p>
</section>
</section>
<section id="data-preprocessing" class="level2">
<h2 class="anchored" data-anchor-id="data-preprocessing">Data Preprocessing</h2>
<p>Abstracts and their metadata were categorised into two corpuses based on their publication date relative to the date of lecanemab’s accelerated early approval, 06-01-2023 <span class="citation" data-cites="Office_of_the_Commissioner2023-hu">(<a href="#ref-Office_of_the_Commissioner2023-hu" role="doc-biblioref">17</a>)</span>. Full abstract text was tokenised into single words using the <em>unnest_tokens</em> function of the <em>tidytext</em> package <span class="citation" data-cites="Silge2016-jf">(<a href="#ref-Silge2016-jf" role="doc-biblioref">36</a>)</span> (<a href="#fig-preprocess-1">Figure&nbsp;2 (a)</a>). The same function was used for tokenising to bigrams and trigrams, using n = 2 and n = 3 respectively. Stop words from the <em>tidytext</em> package <span class="citation" data-cites="Silge2016-jf">(<a href="#ref-Silge2016-jf" role="doc-biblioref">36</a>)</span> combined with the personalised words frequent to the unigram analysis, “<em>alzheimer’s</em>” and “<em>ad</em>”, were then removed (<a href="#fig-preprocess-2">Figure&nbsp;2 (b)</a>). To prevent the different spellings of the same phrase from being counted multiple times, similar bigrams and trigrams were mapped to the same variable. For example, ‘<em>amyloid β</em>, ‘<em>beta amyloid</em>’, and ‘<em>amyloid aβ</em>’ were all mapped to ‘<em>amyloid beta</em>’, and ‘<em>mild cognitive impairments</em>’ and ‘<em>cognitive impairment mci</em>’ were mapped to ‘<em>mild cognitive impairment</em>’. Additionally, for bigrams originating from trigrams, mapping to the first two terms was used or mapping to an acronym, for example ‘<em>central nervous</em>’, ‘<em>system cns’</em> were mapped to’<em>cns</em>’.</p>
<div id="fig-preprocess" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="center" data-hash="report_cache/html/fig-preprocess_39de6480b84073cfff68129962a799e9">
<div class="cell-output-display">
<div id="fig-preprocess-1" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="data/preprocess1.png" class="img-fluid figure-img" data-ref-parent="fig-preprocess" width="480"></p>
<figcaption class="figure-caption">(a) Unigram Tokenisation.</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-preprocess-2" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="data/preprocess2.png" class="img-fluid figure-img" data-ref-parent="fig-preprocess" width="480"></p>
<figcaption class="figure-caption">(b) Removal of Stop Words.</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;2: <strong>Abstract preprocessing into unigrams.</strong> Schematic of an abstract being (A) tokenised into single-word tokens followed by (B) removal of stop words obtained from the <em>tidytext</em> package <span class="citation" data-cites="Silge2016-jf">(<a href="#ref-Silge2016-jf" role="doc-biblioref">36</a>)</span> and personalised words frequent to the unigram analysis, ‘<em>alzheimers</em>’, and ‘<em>AD</em>’. Tokenisation and data cleaning of bigrams and trigrams followed the same methods, not shown.</figcaption>
</figure>
</div>
</section>
<section id="data-analysis" class="level2">
<h2 class="anchored" data-anchor-id="data-analysis">Data Analysis</h2>
<section id="metadata-analysis" class="level3">
<h3 class="anchored" data-anchor-id="metadata-analysis">Metadata Analysis</h3>
<p>The number of relevant abstracts published per month were visualised as well as the frequency of dates of publications for papers containing the associated terminology for the AD drug lecanemab were also obtained.</p>
</section>
<section id="term-frequency" class="level3">
<h3 class="anchored" data-anchor-id="term-frequency">Term Frequency</h3>
<section id="n-gram-frequency-analysis" class="level4">
<h4 class="anchored" data-anchor-id="n-gram-frequency-analysis">N-gram Frequency Analysis</h4>
<p>After tokenisation, the top 20 most frequent unigrams were determined for each dataset. The top 20 most frequent bigrams and trigrams were also determined due to many unigrams being associated with pairs or triplets of words. For example, “mild cognitive impairment” relates to a neurological condition, whereas the words “mild”, “cognitive” and “impairment” have ambiguous connotations individually.</p>
</section>
<section id="term-usage-over-time" class="level4">
<h4 class="anchored" data-anchor-id="term-usage-over-time">Term Usage Over Time</h4>
<p>The distribution of terms used over 1000 times from the unigram analysis was visualised. Generalised linear model (GLM) was used to determine whether there was a significant change in word usage over the months.</p>
</section>
</section>
<section id="topic-modelling" class="level3">
<h3 class="anchored" data-anchor-id="topic-modelling">Topic Modelling</h3>
<p>A document term matrix (dtm) was constructed for each dataset, indicating each word’s term frequency (tf), which is a measure of how often a word appears in each abstract To determine if a statistical model could distinguish between the text corpuses surrounding the accelerated approval date of lecanemab, a two-topic Latent Dirich Allocation (LDA) model <span class="citation" data-cites="Blei2003-lh">(<a href="#ref-Blei2003-lh" role="doc-biblioref">27</a>)</span> was applied to the dtm using <em>topicmodels</em> <span class="citation" data-cites="Grun2011-do">(<a href="#ref-Grun2011-do" role="doc-biblioref">37</a>)</span>. The per-document-per-topic probabilities (γ) was extracted to show the proportion of words generated in each topic and how often these words appear in either corpuses.</p>
<p>Two ten-topic LDA models were also created, one for each text corpuses, to determine the most frequent topics, where an arbitrary topic number (k) of ten was chosen. The per-topic-per-word probabilities (β) were extracted and the top 10 terms most common words found in each topic were visualised. In each model the abstracts are considered mixtures of topics and each topic is considered a mixture of words.</p>
</section>
</section>
</section>
<section id="results-and-discussion" class="level1">
<h1>Results and Discussion</h1>
<p>A full summary of the results is found in <a href="#fig-results-summary">Figure&nbsp;3</a>.</p>
<div id="fig-results-summary" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="centre" data-hash="report_cache/html/fig-results-summary_6e557a8bbcb7b9479634880094319b18">
<div class="cell-output-display">
<div id="fig-results-summary" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="data/resultsummary.png" class="img-fluid figure-img" data-ref-parent="fig-results-summary" width="480"></p>
<figcaption class="figure-caption">(a)</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;3: <strong>Summary of Results</strong></figcaption>
</figure>
</div>
<section id="search-query-refinement-identified-the-term-alzheimer" class="level2">
<h2 class="anchored" data-anchor-id="search-query-refinement-identified-the-term-alzheimer">Search Query Refinement Identified the Term ‘alzheimer’</h2>
<p>Out initial search query was refined using <em>litsearchr</em> <span class="citation" data-cites="Grames2019-as">(<a href="#ref-Grames2019-as" role="doc-biblioref">33</a>)</span> to determine the most important terms to the articles ranked by their strength (<a href="#fig-ad-search-terms">Figure&nbsp;4</a>). We disregarded ‘<em>alzheimer’s disease</em>’ as this MeSH term was included in the original search query, but we updated the PubMed search query with ‘<em>alzheimer</em>’ (<a href="#tbl-inclusion-criteria">Table&nbsp;1</a>). We omitted the unigram ‘<em>disease</em>’ as it was too broad and may have encapsulated articles concerning other irrelevant neurodegenerative diseases into our query.</p>
<p>Due to our search strategy, a lot of papers contain the MeSH term ‘Alzheimer’s disease’ may have been mentioned as a collective with other neurodegenerative diseases. MeSH terms are added manually to articles in PubMed, therefore there could also be a bias when authors add these to their publications. We tried to avoid this by filtering the titles and abstracts of PubMed articles to also contain the term ‘<em>alzheimer’s disease</em>’, ‘<em>ad</em>’ or ‘<em>alzheimer</em>’. Similarly when MeSH terms were not available for the bioRxiv and medRxv databases, we used a similar search strategy to filter titles and abstract text to contain the term ‘<em>alzheimer’s disease</em>’ or ‘<em>alzheimer</em>’, or ‘<em>ad</em>’ and ‘<em>alzheimer’s disease</em>’. Whilst this filtering would have biased our dataset as abstracts not containing these search terms were ommitted, we were still able to gain a large dataset of 6744 abstracts that were published between 01-01-2022 and 30-12-2023.</p>
<div id="fig-ad-search-terms" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="left" data-hash="report_cache/html/fig-ad-search-terms_5619dec24c29c52553aae6b5dd741625">
<div class="cell-output-display">
<div id="fig-ad-search-terms" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-ad-search-terms-1.png" class="img-fluid figure-img" data-ref-parent="fig-ad-search-terms" width="1440"></p>
<figcaption class="figure-caption">(a)</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;4: <strong>Search query refinement using <em>litsearchr</em> identified ‘<em>alzheimer</em>’.</strong> A matrix of each word in each article was created and the potential search terms were ranked with <em>create_network</em> and <em>strength</em> <span class="citation" data-cites="Barrat2004-hm">(<a href="#ref-Barrat2004-hm" role="doc-biblioref">34</a>)</span> from the <em>igraph</em> package <span class="citation" data-cites="Csardi2006-gb">(<a href="#ref-Csardi2006-gb" role="doc-biblioref">35</a>)</span>. The top keywords and words from the titles of AD papers, with minimum frequencies of n = 50 and n = 75, respectively, were ranked by their importance to article content. The dashed lines mark optimal cutoff positions where the trend in strength shows sharp changes.</figcaption>
</figure>
</div>
</section>
<section id="ad-research-publication-frequency-is-not-associated-with-lecanemab-approval" class="level2">
<h2 class="anchored" data-anchor-id="ad-research-publication-frequency-is-not-associated-with-lecanemab-approval">AD Research Publication Frequency is not Associated with Lecanemab Approval</h2>
<p>Lecanemab received accelerated and traditional approval in 2023 <span class="citation" data-cites="Office_of_the_Commissioner2023-hu Office_of_the_Commissioner2023-ka">(<a href="#ref-Office_of_the_Commissioner2023-hu" role="doc-biblioref">17</a>,<a href="#ref-Office_of_the_Commissioner2023-ka" role="doc-biblioref">38</a>)</span>, however we did not find any variability in the overall frequency of literature published containing the MeSH term ‘<em>Alzheimer’s Disease</em>’ <a href="#fig-publication-date-1">Figure&nbsp;5 (a)</a>. Despite the frequency of publications containing the terms associated with the AD drug lecanemab exponentially increasing in 2023 (<a href="#fig-publication-date-2">Figure&nbsp;5 (b)</a>), there was no significant difference between the per-document-per-topic probabilities (γ) for the two-topic LDA models (<a href="#fig-gamma-lda">Figure&nbsp;6</a>). This suggests that the content of the abstracts did not change significantly after the accelerated approval of lecanemab.</p>
<div id="fig-publication-date" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="left" data-hash="report_cache/html/fig-publication-date_3a3413ccfb0c523d9c2273edf753c374">
<div class="cell-output-display">
<div id="fig-publication-date-1" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-publication-date-1.png" class="img-fluid figure-img" data-ref-parent="fig-publication-date" width="1440"></p>
<figcaption class="figure-caption">(a) All Abstracts</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-publication-date-2" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-publication-date-2.png" class="img-fluid figure-img" data-ref-parent="fig-publication-date" width="1440"></p>
<figcaption class="figure-caption">(b) Lecanemab Abstracts</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;5: <strong>Frequency of lecanemab publications increases in 2023.</strong> Distribution of articles published over time containing (A) the MeSH term ‘Alzheimer’s Disease’ in the title and/or abstract (n = 6744) or (B) terms associated with the AD drug lecanemab: ‘<em>lecanemab</em>’, ‘<em>leqembi</em>’, ‘<em>BAN2401</em>’, and ‘<em>mAb158</em>’ (n = 207). Dashed-line represents date of lecanemab accelerated approval, 06-01-2023.</figcaption>
</figure>
</div>
<p>One reason for there not being any statistical significance between the per-document-per-topic probabilities could be due to the two-year time period being too short to account for a change in the research landscape as previous studies have used a five-year time period to characterise topics in AD literature <span class="citation" data-cites="Martinelli2022-ic">(<a href="#ref-Martinelli2022-ic" role="doc-biblioref">28</a>)</span>. This suggests that the topics in the period after the accelerated approval of lecanemab were not different to the topics in the year before lecanemab was approved. We found 3,468 abstracts published before and 3,276 abstracts published after the accelerated approval of lecanemab which is one of the largest per-year abstract corpuses concerning AD. Further research should explore a larger time period after the accelerated approval to conclude whether a change in the research literature can be found using topic models. This would suggest that our one-year analysis was too short as changes in AD research are slow and takes multiple years.</p>
<div id="fig-gamma-lda" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="left" data-hash="report_cache/html/fig-gamma-lda_36de1e1669b88862b1944b13165a6fa0">
<div class="cell-output-display">
<div id="fig-gamma-lda" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-gamma-lda-1.png" class="img-fluid figure-img" data-ref-parent="fig-gamma-lda" width="1440"></p>
<figcaption class="figure-caption">(a)</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;6: <strong>Two topic LDA model does not distinguish change in literature around accelerated approval date of Lecanemab</strong>. A document term matrix (dtm) was constructed for the unigram dataset and a two topic LDA model was applied to the dtm using <em>topicmodels</em> <span class="citation" data-cites="Grun2011-do">(<a href="#ref-Grun2011-do" role="doc-biblioref">37</a>)</span>. Boxplots show first and third quartiles, median and outlier per-document-per-topic probabilities, γ. Corpus type was determined based on accelerated approval date for lecanemab, 06-01-2023. n = 6744.</figcaption>
</figure>
</div>
<p>Despite the full abstract dataset not significantly splitting into two distinct topics, we aimed to suggest this was because the language was very similar between the two corpses. We therefore aimed to explore the most common n-grams frequencies. ‘<em>Disease</em>’ was the most frequent unigram in both corpuses (<a href="#fig-tokenisation-1">Figure&nbsp;7 (a)</a>) and was included with ‘<em>neurodegenerative disease</em>’, ‘<em>Parkinson’s disease</em>’, and ‘<em>Huntington’s disease</em>’ which were among the most frequent bigrams and trigrams (<a href="#fig-tokenisation-2">Figure&nbsp;7 (b)</a>; <a href="#fig-tokenisation-3">Figure&nbsp;7 (c)</a>). Fourteen of the top fifteen most common unigrams were shared between the two corpuses, however there were no significant differences between the unigram frequencies over time (<a href="#fig-tokenisation-4">Figure&nbsp;7 (d)</a>). Similarly, fourteen of top fifteen bigrams and trigrams were shared between the two corpuses. This suggests that the word usage has remained consistent and indicating that the introduction of a novel anti-amyloid therapy may not have changed the research landscape during the observed period.</p>
<div id="fig-tokenisation" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="left" data-hash="report_cache/html/fig-tokenisation_18b13effa2ab34ccb64055949cc6bd2b">
<div class="cell-output-display">
<div id="fig-tokenisation-1" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-tokenisation-1.png" class="img-fluid figure-img" data-ref-parent="fig-tokenisation" width="1440"></p>
<figcaption class="figure-caption">(a) Unigram</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-tokenisation-2" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-tokenisation-2.png" class="img-fluid figure-img" data-ref-parent="fig-tokenisation" width="1440"></p>
<figcaption class="figure-caption">(b) Bigram</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-tokenisation-3" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-tokenisation-3.png" class="img-fluid figure-img" data-ref-parent="fig-tokenisation" width="1440"></p>
<figcaption class="figure-caption">(c) Trigram</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-tokenisation-4" class="quarto-figure quarto-figure-left anchored">
<figure class="figure">
<p><img src="report_files/figure-html/fig-tokenisation-4.png" class="img-fluid figure-img" data-ref-parent="fig-tokenisation" width="1440"></p>
<figcaption class="figure-caption">(d) Most common words</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;7: <strong>Literature use is similar around the time of lecanemab approval.</strong> Corpus type was determined based on accelerated approval date for lecanemab, 06-01-2023 then tokenised and removal of stop words. The 15 most frequent (A) unigrams, (B) bigrams and (C) trigrams along with (D) the distribution by month of the top 14 shared most frequent unigrams for both corpuses (n = 6744). Dashed-line represents the accelerated approval date of lecanemab, 06-01-2023.</figcaption>
</figure>
</div>
<section id="research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval" class="level3">
<h3 class="anchored" data-anchor-id="research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval">Research concerning genetic risk and molecular pathology were prominent before lecanemab underwent accelerated approval</h3>
<p>The n-gram analysis suggested that term usage has not changed around the accelerated approval of lecanemab, so we used LDA topic modelling to see whether the terms may be distributed differently in topics in each corpus. In the year before the accelerated approval of lecanemab, we found ten topics with the top ten keywords (<a href="#fig-topic-model-unigrams-1">Figure&nbsp;8 (a)</a>). The first topic concerned genetics, specifically mentioning ‘genes’ and ‘genetic’ as well as ‘covid’ and ‘19’ as genetic links have been hypothesised between having COVID-19 and developing AD @<span class="citation" data-cites="Matveeva2023-nz Baranova2023-ba">(<a href="#ref-Matveeva2023-nz" role="doc-biblioref">39</a>,<a href="#ref-Baranova2023-ba" role="doc-biblioref">40</a>)</span>. Multiple topics referenced study terminology, either relating to pre-clinical drug discovery in ‘cells’ and ‘models’ or clinical studies such as ‘trials’, ‘human’ which could be related to the increase in clinical trials <span class="citation" data-cites="Huang2023-vq">(<a href="#ref-Huang2023-vq" role="doc-biblioref">24</a>)</span>. As the cause of AD is not full understood, topics concerning the molecular pathology, specifically referencing the ‘amyloid-beta’ and ‘tau’, were identified which highlight the importance of these hypotheses. Topics concerning cellular pathology such as ‘migroglia’ and ‘mitochondria’ may be referring to the increased neuroinflammation relating to AD and recruitment of immune cells, as well as oxidative stress from neuronal death (<span class="citation" data-cites="ref">(<a href="#ref-ref" role="doc-biblioref"><strong>ref?</strong></a>)</span>). Imaging techniques such as ‘pet’ and diagnostic markers from cerebrospinal fluid (CSF) represented another topic. Finally topics relating to brain function and neurodegeneration</p>
<p>Like previously found, topics concerning study treatments including … What were terms in martinelli [<span class="citation" data-cites="Martinelli2022-ic">(<a href="#ref-Martinelli2022-ic" role="doc-biblioref">28</a>)</span>].</p>
</section>
<section id="research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval-1" class="level3">
<h3 class="anchored" data-anchor-id="research-concerning-genetic-risk-and-molecular-pathology-were-prominent-before-lecanemab-underwent-accelerated-approval-1">Research concerning genetic risk and molecular pathology were prominent before lecanemab underwent accelerated approval</h3>
<p>n the year before the accelerated approval of lecanemab, we found ten topics with the top ten keywords (<a href="#fig-topic-model-unigrams-2">Figure&nbsp;8 (b)</a>).</p>
<p>The topics <em>‘Treatments’</em>, <em>‘AD Diagnosis’</em>, <em>‘Genetic Risk’</em>, <em>‘Molecular Pathology’</em>, ’<em>Study Terminology’</em> and <em>‘Cellular Pathology’</em> were observed in abstracts before and after the accelerated approval of lecanemab <a href="#fig-topic-model-unigrams">Figure&nbsp;8</a>.</p>
<div id="fig-topic-model-unigrams" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<div class="cell" data-layout-align="center" data-hash="report_cache/html/fig-topic-model-unigrams_77c2c61662ed12152eb7148ad349f26f">
<div class="cell-output-display">
<div id="fig-topic-model-unigrams-1" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="plots/pre-leca-lda-grey.png" class="img-fluid figure-img" data-ref-parent="fig-topic-model-unigrams" width="1012"></p>
<figcaption class="figure-caption">(a) Pre-Lecenamab Accelerated Approval: Top 10 unigrams in each LDA topic</figcaption>
</figure>
</div>
</div>
<div class="cell-output-display">
<div id="fig-topic-model-unigrams-2" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="plots/post-leca-lda-blue2.png" class="img-fluid figure-img" data-ref-parent="fig-topic-model-unigrams" width="1012"></p>
<figcaption class="figure-caption">(b) Post-Lecanemab Accelerated Approval: Top 10 unigrams in each LDA topic</figcaption>
</figure>
</div>
</div>
</div>
<figcaption class="figure-caption">Figure&nbsp;8: <strong>Unigram LDA Topic Modelling.</strong> Outputs from the ten-topic LDA model for abstracts published (A) before and (B) after the accelerated approval date of lecenamab, 2023-01-06. The top 10 unigrams per topic are ordered by their per-topic-per-word probability, β. Topic titles were manually created and added. Colours are arbitory and match when the same topic was identified from (A) to (B), else are gray.</figcaption>
</figure>
</div>
</section>
<section id="tau-research-may-be-increasing-after-lecanemab-accelerated-approval." class="level3">
<h3 class="anchored" data-anchor-id="tau-research-may-be-increasing-after-lecanemab-accelerated-approval.">Tau research may be increasing after lecanemab accelerated approval.</h3>
<p>Topics containing study terminology were common to both corpuses, however the unigram ‘<em>placebo</em>’ was unique to the later corpus. This could suggest an increase in the number of randomised clinical trials (RCT) after lecanemab received accelerated approval as these trials usually involve a placebo-control. This is consistent with the trends observed in <span class="citation" data-cites="Huang2023-vq">(<a href="#ref-Huang2023-vq" role="doc-biblioref">24</a>)</span> which suggest an increase in Phase III clinical trials for anti-amyloid therapies and encompasses the traditonal approval date of lecanemab by the FDA in July 2023 from the Clarity AD clinical trial <span class="citation" data-cites="Office_of_the_Commissioner2023-ka">(<a href="#ref-Office_of_the_Commissioner2023-ka" role="doc-biblioref">38</a>)</span>. Placebos are used when there is no known or FDA-approved therapy that can be tolerated by patients, therefore as AD does not have a standard of care treatment to cure the disease, a placebo may be used in RCTs.</p>
<p>We aimed to see whether there had been a change in the terms found in similar topics between the two corpuses. There was an increase in the beta-value for the terms in the ‘<em>Molecular Pathology’</em> topic after the accelerated approval of lecanemab, specifically for the terms:’<em>tau’</em>, ’<em>amyloid’,</em> and <em>‘aβ’.</em> This suggests these unigrams were more associated with topics in the latter corpus.</p>
<p>The term ‘<em>insulin</em>’ was not found in the later corpus <a href="#fig-topic-model-unigrams-2">Figure&nbsp;8 (b)</a>, however ’<em>type 2 diabetes’</em> was one of the most common trigrams for both corpuses (<a href="#fig-tokenisation-3">Figure&nbsp;7 (c)</a>). AD has been referred to as type 3 diabetes due to the rapid growth of literature concerning brain insulin resistance and experimental evidence has shown insulin sensitiser treatments may help attenuate learning deficits <span class="citation" data-cites="De_la_Monte2008-uy Reger2008-xj Pedersen2006-pl Reger2006-nq">(<a href="#ref-De_la_Monte2008-uy" role="doc-biblioref">41</a>–<a href="#ref-Reger2006-nq" role="doc-biblioref">44</a>)</span>. Many epidemiological studies have suggested T2DM may be increasing the risk of AD, leading to the lower brain insulin levels resulting in decreased clearance of amyloid-beta <span class="citation" data-cites="Gasparini2001-up Ott1999-pv">(<a href="#ref-Gasparini2001-up" role="doc-biblioref">45</a>,<a href="#ref-Ott1999-pv" role="doc-biblioref">46</a>)</span>. Despite this growing area of research, observations between non-demented participants and AD patients with T2DM have not been able to show a significant difference in amyloid accumulation <span class="citation" data-cites="Cholerton2016-iz">(<a href="#ref-Cholerton2016-iz" role="doc-biblioref">47</a>)</span>. Whilst we cannot conclude from our results whether this suggests a shift in research focusing on T2DM and its metabolic link to AD, we have observed that literature around the approval of lecanemab does concern multiple metabolic and immune changes relating to AD.</p>
<p>We found topics that contained general terms relating to neurodegenerative diseases and research in both text corpuses, however this may be due to us using only abstract text which only provides a summary of the larger article text. Further research should replicate our methodology using full article text to validate our results, however abstracts represent a concise summary of articles, so the main keywords should be included here. Despite this, some major topics may be lost by omitting the full article text.</p>
<p>We only used abstracts written in English, so we may be missing abstracts that have not been translated from other languages and concern AD.</p>
<p>We only used abstracts!!! More information will be in the main text. Limited due to data collection strategies, therefore in the future should be able to mine more</p>
<p>Our suggest that the introduction of lecanemab has not had a significant impact on the research landscape of Alzheimer’s disease in the years either side of its accelerated approval. Using text from abstracts of articles, we did not find any major changes using LDA topic modelling. While <em>in silico</em> methods of literature reviewing are useful to disseminate large quantities of text data, we would suggest they are not as robust as human input. We do however think that this automated approach could help provide an overview of major topics and increase the efficiency of understanding the large volume of studies in the AD literature. We hope this could help in the journey to find a cure for this devastating disease.</p>
</section>
</section>
</section>


<div id="quarto-appendix" class="default"><section id="acknowledgements" class="level1 appendix"><h2 class="anchored quarto-appendix-heading">Acknowledgements</h2><div class="quarto-appendix-contents">

<p>I would like to thank my supervisor Emma Rand for her constant support and guidance throughout my project. I would also like to dedicate this project to my late granddad Alan Scrimshire who passed away on the 31st March 2023 after fighting a five year battle with Alzheimer’s Disease. I hope this project highlights the complexity of the disease and the vast efforts being undertaken to find a cure.</p>

</div></section><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" role="list">
<div id="ref-World_Health_Organization2023-eb" class="csl-entry" role="listitem">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">World Health Organization. Dementia. <a href="https://www.who.int/news-room/fact-sheets/detail/dementia" class="uri">https://www.who.int/news-room/fact-sheets/detail/dementia</a>; 2023. </div>
</div>
<div id="ref-2023_Alzheimers_disease_facts_and_figures2023-ek" class="csl-entry" role="listitem">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">2023 Alzheimer’s disease facts and figures. 2023 alzheimer’s disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598–695. </div>
</div>
<div id="ref-Villemagne2013-xk" class="csl-entry" role="listitem">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid <span class="math inline">\(\beta\)</span> deposition, neurodegeneration, and cognitive decline in sporadic alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2013 Apr;12(4):357–67. </div>
</div>
<div id="ref-Iaccarino2018-ta" class="csl-entry" role="listitem">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi M, Kramer JH, Lazaris A, Lockhart SN, Miller BL, Miller ZA, O’Neil JP, Ossenkoppele R, Rosen HJ, Schonhaut DR, Jagust WJ, Rabinovici GD. Local and distant relationships between amyloid, tau and neurodegeneration in alzheimer’s disease. Neuroimage Clin. 2018;17:452–64. </div>
</div>
<div id="ref-Garcia-Morales2021-zb" class="csl-entry" role="listitem">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Garcı́a-Morales V, González-Acedo A, Melguizo-Rodrı́guez L, Pardo-Moreno T, Costela-Ruiz VJ, Montiel-Troya M, Ramos-Rodrı́guez JJ. Current understanding of the physiopathology, diagnosis and therapeutic approach to alzheimer’s disease. Biomedicines. 2021 Dec;9(12). </div>
</div>
<div id="ref-Janeiro2021-sg" class="csl-entry" role="listitem">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Janeiro MH, Ardanaz CG, Sola-Sevilla N, Dong J, Cortés-Erice M, Solas M, Puerta E, Ramı́rez MJ. Biomarcadores en la enfermedad de alzheimer. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio. 2021 Mar;2(1):39–50. </div>
</div>
<div id="ref-Odusami2021-pp" class="csl-entry" role="listitem">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Odusami M, Maskeliūnas R, Damaševičius R, Krilavičius T. Analysis of features of alzheimer’s disease: Detection of early stage from functional brain changes in magnetic resonance images using a finetuned <span>ResNet18</span> network. Diagnostics (Basel). 2021 Jun;11(6). </div>
</div>
<div id="ref-A_Armstrong2019-go" class="csl-entry" role="listitem">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">A Armstrong R. Risk factors for alzheimer’s disease. Folia Neuropathol. 2019;57(2):87–105. </div>
</div>
<div id="ref-Henderson1988-cr" class="csl-entry" role="listitem">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Henderson AS. The risk factors for alzheimer’s disease: A review and a hypothesis. Acta Psychiatr Scand. 1988 Sep;78(3):257–75. </div>
</div>
<div id="ref-Matthews2013-vu" class="csl-entry" role="listitem">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C, Medical Research Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of england: Results of the cognitive function and ageing study <span>I</span> and <span>II</span>. Lancet. 2013 Oct;382(9902):1405–12. </div>
</div>
<div id="ref-Colovic2013-it" class="csl-entry" role="listitem">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol. 2013 May;11(3):315–35. </div>
</div>
<div id="ref-Courtney2004-br" class="csl-entry" role="listitem">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with alzheimer’s disease (<span>AD2000)</span>: Randomised double-blind trial. Lancet. 2004 Jun;363(9427):2105–15. </div>
</div>
<div id="ref-Long2019-qm" class="csl-entry" role="listitem">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 2019 Oct;179(2):312–39. </div>
</div>
<div id="ref-Folch2018-vb" class="csl-entry" role="listitem">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Folch J, Busquets O, Ettcheto M, Sánchez-López E, Castro-Torres RD, Verdaguer E, Garcia ML, Olloquequi J, Casadesús G, Beas-Zarate C, Pelegri C, Vilaplana J, Auladell C, Camins A. Memantine for the treatment of dementia: A review on its current and future applications. J Alzheimers Dis. 2018;62(3):1223–40. </div>
</div>
<div id="ref-Rogawski2003-od" class="csl-entry" role="listitem">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of alzheimer’s disease. CNS Drug Rev. 2003 Sep;9(3):275–308. </div>
</div>
<div id="ref-Center_for_Drug_Evaluation2023-gy" class="csl-entry" role="listitem">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Center for Drug Evaluation, Research. <span class="nocase">FDA’s</span> decision to approve new treatment for alzheimer’s disease. <a href="https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease" class="uri">https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease</a>; FDA; 2023. </div>
</div>
<div id="ref-Office_of_the_Commissioner2023-hu" class="csl-entry" role="listitem">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Office of the Commissioner. <span>FDA</span> grants accelerated approval for alzheimer’s disease treatment. <a href="https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment" class="uri">https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment</a>; FDA; 2023. </div>
</div>
<div id="ref-Alexander2021-ln" class="csl-entry" role="listitem">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021 May;325(17):1717–8. </div>
</div>
<div id="ref-Mahase2021-no" class="csl-entry" role="listitem">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Mahase E. Aducanumab: European agency rejects alzheimer’s drug over efficacy and safety concerns. BMJ. 2021 Dec;375:n3127. </div>
</div>
<div id="ref-noauthor_undated-ml" class="csl-entry" role="listitem">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">The scientific advisory group (sag) to convene to discuss the marketing authorization application for lecanemab in the eu. <a href="https://www.eisai.com/news/2024/news202404.html" class="uri">https://www.eisai.com/news/2024/news202404.html</a>; </div>
</div>
<div id="ref-Sevigny2016-yx" class="csl-entry" role="listitem">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces <span>A<span class="math inline">\(\beta\)</span></span> plaques in alzheimer’s disease. Nature. 2016 Sep;537(7618):50–6. </div>
</div>
<div id="ref-Brenman2023-ki" class="csl-entry" role="listitem">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Brenman JE. Lecanemab in early alzheimer’s disease. N Engl J Med. 2023 Apr;388(17):1631. </div>
</div>
<div id="ref-Cummings2023-lo" class="csl-entry" role="listitem">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement. 2023 May;9(2):e12385. </div>
</div>
<div id="ref-Huang2023-vq" class="csl-entry" role="listitem">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Huang L-K, Kuan Y-C, Lin H-W, Hu C-J. Clinical trials of new drugs for alzheimer disease: A 2020–2023 update. J Biomed Sci. 2023 Oct;30(1):83. </div>
</div>
<div id="ref-Gustavsson2023-qr" class="csl-entry" role="listitem">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, Flier WM van der. Global estimates on the number of persons across the alzheimer’s disease continuum. Alzheimers Dement. 2023 Feb;19(2):658–70. </div>
</div>
<div id="ref-Higgins2019-kn" class="csl-entry" role="listitem">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">Higgins JPT. Cochrane handbook for systematic reviews of interventions. 2nd ed. Higgins J, Thomas J, editors. Hoboken, NJ: Wiley-Blackwell; 2019. (Wiley cochrane series). </div>
</div>
<div id="ref-Blei2003-lh" class="csl-entry" role="listitem">
<div class="csl-left-margin">27. </div><div class="csl-right-inline">Blei DM, Ng AY, Jordan MI. Latent dirichlet allocation. <a href="https://www.jmlr.org/papers/volume3/blei03a/blei03a.pdf?ref=https://githubhelp.com" class="uri">https://www.jmlr.org/papers/volume3/blei03a/blei03a.pdf?ref=https://githubhelp.com</a>; 2003. </div>
</div>
<div id="ref-Martinelli2022-ic" class="csl-entry" role="listitem">
<div class="csl-left-margin">28. </div><div class="csl-right-inline">Martinelli DD. Evolution of alzheimer’s disease research from a health-tech perspective: Insights from text mining. International Journal of Information Management Data Insights. 2022 Nov;2(2):100089. </div>
</div>
<div id="ref-Greco2012-pv" class="csl-entry" role="listitem">
<div class="csl-left-margin">29. </div><div class="csl-right-inline">Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kłoszewska I, Tsolaki M, Vellas B, Spenger C, Mecocci P, Wahlund L-O, Simmons A, Barnes J, Lovestone S. Alzheimer’s disease biomarker discovery using in silico literature mining and clinical validation. J Transl Med. 2012 Oct;10:217. </div>
</div>
<div id="ref-Nian2022-xw" class="csl-entry" role="listitem">
<div class="csl-left-margin">30. </div><div class="csl-right-inline">Nian Y, Hu X, Zhang R, Feng J, Du J, Li F, Bu L, Zhang Y, Chen Y, Tao C. Mining on alzheimer’s diseases related knowledge graph to identity potential <span class="nocase">AD-related</span> semantic triples for drug repurposing. BMC Bioinformatics. 2022 Sep;23(Suppl 6):407. </div>
</div>
<div id="ref-Wickham2019-rj" class="csl-entry" role="listitem">
<div class="csl-left-margin">31. </div><div class="csl-right-inline">Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. Welcome to the <span></span>tidyverse<span></span>. 2019;4:1686. </div>
</div>
<div id="ref-Kovalchik2021-xq" class="csl-entry" role="listitem">
<div class="csl-left-margin">32. </div><div class="csl-right-inline">Kovalchik S. <span>RISmed</span>: Download content from <span>NCBI</span> databases. 2021; </div>
</div>
<div id="ref-Grames2019-as" class="csl-entry" role="listitem">
<div class="csl-left-margin">33. </div><div class="csl-right-inline">Grames EM, Stillman AN, Tingley MW, Elphick CS. An automated approach to identifying search terms for systematic reviews using keyword co‐occurrence networks. Methods Ecol Evol. 2019 Oct;10(10):1645–54. </div>
</div>
<div id="ref-Barrat2004-hm" class="csl-entry" role="listitem">
<div class="csl-left-margin">34. </div><div class="csl-right-inline">Barrat A, Barthélemy M, Pastor-Satorras R, Vespignani A. The architecture of complex weighted networks. Proc Natl Acad Sci U S A. 2004 Mar;101(11):3747–52. </div>
</div>
<div id="ref-Csardi2006-gb" class="csl-entry" role="listitem">
<div class="csl-left-margin">35. </div><div class="csl-right-inline">Csardi G, Nepusz T. The igraph software package for complex network research. 2006;Complex Systems:1695. </div>
</div>
<div id="ref-Silge2016-jf" class="csl-entry" role="listitem">
<div class="csl-left-margin">36. </div><div class="csl-right-inline">Silge J, Robinson D. Tidytext: Text mining and analysis using tidy data principles in <span>R</span>. 2016;1. </div>
</div>
<div id="ref-Grun2011-do" class="csl-entry" role="listitem">
<div class="csl-left-margin">37. </div><div class="csl-right-inline">Grün B, Hornik K. Topicmodels: An <span>R</span> package for fitting topic models. J Stat Softw. 2011 May;40:1–30. </div>
</div>
<div id="ref-Office_of_the_Commissioner2023-ka" class="csl-entry" role="listitem">
<div class="csl-left-margin">38. </div><div class="csl-right-inline">Office of the Commissioner. <span>FDA</span> converts novel alzheimer’s disease treatment to traditional approval. <a href="https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval" class="uri">https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval</a>; FDA; 2023. </div>
</div>
<div id="ref-Matveeva2023-nz" class="csl-entry" role="listitem">
<div class="csl-left-margin">39. </div><div class="csl-right-inline">Matveeva N, Kiselev I, Baulina N, Semina E, Kakotkin V, Agapov M, Kulakova O, Favorova O. Shared genetic architecture of <span>COVID-19</span> and alzheimer’s disease. Front Aging Neurosci. 2023 Oct;15:1287322. </div>
</div>
<div id="ref-Baranova2023-ba" class="csl-entry" role="listitem">
<div class="csl-left-margin">40. </div><div class="csl-right-inline">Baranova A, Cao H, Zhang F. Causal effect of <span>COVID-19</span> on alzheimer’s disease: A mendelian randomization study. J Med Virol. 2023 Jan;95(1):e28107. </div>
</div>
<div id="ref-De_la_Monte2008-uy" class="csl-entry" role="listitem">
<div class="csl-left-margin">41. </div><div class="csl-right-inline">Monte SM de la, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008 Nov;2(6):1101–13. </div>
</div>
<div id="ref-Reger2008-xj" class="csl-entry" role="listitem">
<div class="csl-left-margin">42. </div><div class="csl-right-inline">Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JCS, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early <span>AD</span>. Neurology. 2008 Feb;70(6):440–8. </div>
</div>
<div id="ref-Pedersen2006-pl" class="csl-entry" role="listitem">
<div class="csl-left-margin">43. </div><div class="csl-right-inline">Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 alzheimer mice. Exp Neurol. 2006 Jun;199(2):265–73. </div>
</div>
<div id="ref-Reger2006-nq" class="csl-entry" role="listitem">
<div class="csl-left-margin">44. </div><div class="csl-right-inline">Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by <span>APOE</span> genotype. Neurobiol Aging. 2006 Mar;27(3):451–8. </div>
</div>
<div id="ref-Gasparini2001-up" class="csl-entry" role="listitem">
<div class="csl-left-margin">45. </div><div class="csl-right-inline">Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001 Apr;21(8):2561–70. </div>
</div>
<div id="ref-Ott1999-pv" class="csl-entry" role="listitem">
<div class="csl-left-margin">46. </div><div class="csl-right-inline">Ott A, Stolk RP, Harskamp F van, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The rotterdam study. Neurology. 1999 Dec;53(9):1937–42. </div>
</div>
<div id="ref-Cholerton2016-iz" class="csl-entry" role="listitem">
<div class="csl-left-margin">47. </div><div class="csl-right-inline">Cholerton B, Baker LD, Montine TJ, Craft S. Type 2 diabetes, cognition, and dementia in older adults: Toward a precision health approach. Diabetes Spectr. 2016 Nov;29(4):210–9. </div>
</div>
</div></section></div></main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>